---
title: "Agenus Inc. (AGEN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AGEN.US.md"
symbol: "AGEN.US"
name: "Agenus Inc."
industry: "Biotechnology"
datetime: "2026-05-20T09:36:07.952Z"
locales:
  - [en](https://longbridge.com/en/quote/AGEN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AGEN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AGEN.US.md)
---

# Agenus Inc. (AGEN.US)

## Company Overview

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.agenusbio.com](https://www.agenusbio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: C (0.52)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 147 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 24.46% |  |
| Net Profit YoY | 133.75% |  |
| P/B Ratio | -0.54 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 118650913.86 |  |
| Revenue | 123866000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -22.87% | E |
| Profit Margin | 52.16% | A |
| Gross Margin | 100.00% | A |
| Revenue YoY | 24.46% | A |
| Net Profit YoY | 133.75% | A |
| Total Assets YoY | -6.87% | D |
| Net Assets YoY | 29.29% | A |
| Cash Flow Margin | -135.93% | E |
| OCF YoY | 24.46% | A |
| Turnover | 0.64 | B |
| Gearing Ratio | 222.27% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Agenus Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "24.46%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "133.75%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-0.54",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "118650913.86",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "123866000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-22.87%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "52.16%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "24.46%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "133.75%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-6.87%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "29.29%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-135.93%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "24.46%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.64",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "222.27%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 1.84 | 12/386 | - | - | - |
| PB | -0.54 | 470/386 | - | - | - |
| PS (TTM) | 0.96 | 22/386 | 1.42 | 1.28 | 1.07 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-12T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.09 |
| Highest Target | 23.00 |
| Lowest Target | 8.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AGEN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AGEN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/AGEN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AGEN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**